• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi, Sept. 11

Ranbaxy Laboratories Ltd today said it has received approval from the USFDA to manufacture and market Loperamide Hydrochloride and Simethicone tablets. The drug maker informed the BSE that it received approval for manufacturing and marketing the tablets in dosages of 2mg/125mg (over-the-counter).

Loperamide Hydrochloride and Simethicone Tablets (OTC) are indicated for controlling symptoms of diarrhoea plus bloating, pressure, and cramps. "Ohm will again be a leading participant in the launch of another successful and proven Loperamide formulation. This will be marketed on a 180-day exclusive basis in the private label brand segment of major US retailers and wholesalers," the Ohm Laboratories Inc Senior Director (OTC Sales and Marketing), Mr Robert Haywood, said.

Ohm Laboratories, Ranbaxy's US-based subsidiary, is engaged in the sale and distribution of generic and branded private label, OTC products in the US healthcare system.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Grasim to invest Rs 75 cr in Bhiwani plant

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line